Sonire Therapeutics has commenced a randomized Phase 2 study for the treatment of unresectable pancreatic cancer with their next-generation High-Intensity Focused Ultrasound therapy system. Learn more about the Tokyo-based organization in this installment of our Let’s Interview Series.
Venture Valuation (VV) interviewed President and CEO, Mr. Satoh Toru.
Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?